Cannabis and Glaucoma: Where We Stand

Though THC lowers intraocular pressure, its duration profile and systemic effects limit its current clinical role in glaucoma.

Context and Why It Matters

Clinical practice with cannabinoids requires integrating evolving evidence, endocannabinoid pharmacology, and the operational realities of the clinic. Few therapeutic areas demand more methodological humility.

Evidence and Current Practice

International professional guidelines agree on core principles: rigorous eligibility assessment, gradual titration, active monitoring for adverse effects, and periodic reassessment. The difference between good and poor practice lies in follow-through.

Operational Considerations

Drug-drug interactions deserve specific attention. Both THC and CBD modulate hepatic enzymes and can shift serum concentrations of narrow therapeutic index drugs. Polypharmacy review is mandatory.

Bottom Line

Documenting informed consent in sufficient detail protects both patient and prescriber. Clear records also smooth future care transitions and peer review.